B1401
缓激肽片段 1-5
≥97% (HPLC)
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C27H40N8O6
化学文摘社编号:
分子量:
572.66
NACRES:
NA.32
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
Form:
powder
Assay:
≥97% (HPLC)
产品名称
缓激肽片段 1-5, ≥97% (HPLC)
InChI
1S/C27H40N8O6/c28-18(9-4-12-31-27(29)30)24(38)35-14-6-11-21(35)25(39)34-13-5-10-20(34)23(37)32-16-22(36)33-19(26(40)41)15-17-7-2-1-3-8-17/h1-3,7-8,18-21H,4-6,9-16,28H2,(H,32,37)(H,33,36)(H,40,41)(H4,29,30,31)
SMILES string
NC(CCCNC(N)=N)C(=O)N1CCCC1C(=O)N2CCCC2C(=O)NCC(=O)NC(Cc3ccccc3)C(O)=O
InChI key
USSUMSBPLJWFSZ-UHFFFAOYSA-N
assay
≥97% (HPLC)
form
powder
UniProt accession no.
storage temp.
−20°C
Quality Level
Gene Information
human ... KNG1 (includes EG:3827)
Biochem/physiol Actions
缓激肽(BK)片段(1-5)(RPPGF)是最稳定的天然代谢产物之一。可作为体内缓激肽产生的标志物。其生物活性依赖于C末端的一个完整的精氨酸(Arg)残基。BK 1-5是抑制α-凝血酶诱导的血小板聚集和分泌及钙离子动员的必需肽。还可抑制α-凝血酶在精氨酸和丝氨酸之间的位点切割凝血酶受体肽NATLDPRSFLLR。BK 1-5的这种抗凝血酶活性可能与激肽的心脏保护作用有关。
Packaging
无底玻璃瓶。内含物装在锥底内插管中。
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
法规信息
常规特殊物品
此项目有
A A Hasan et al.
Thrombosis and haemostasis, 82(3), 1182-1187 (1999-09-24)
Thrombostatin (RPPGF), an angiotensin converting enzyme metabolite of bradykinin, is an inhibitor of alpha-thrombin's ability to activate platelets. We examined the in vivo pharmacokinetics and pharmacodynamics of thrombostatin in rabbits and its ability to inhibit coronary thrombosis induced by electrolytic
L J Murphey et al.
Circulation, 102(8), 829-832 (2000-08-23)
Bradykinin is a cardioprotective peptide metabolized by the angiotensin-converting enzyme (ACE). An insertion/deletion (I/D) polymorphism in the ACE gene determines plasma ACE levels. The D allele is associated with cardiovascular disease, which may relate to enhanced angiotensin II production or
Marvin T Nieman et al.
Thrombosis and haemostasis, 104(5), 1044-1048 (2010-10-05)
Thrombin stimulates proliferation, invasion and metastasis by cleaving protease-activated receptor 1 (PAR1) on human prostate cancer cells. Current direct thrombin inhibitors pose risks for bleeding in the cancer patients. We have developed an oral reversible direct thrombin inhibitor called FM19.
Mias Pretorius et al.
Arteriosclerosis, thrombosis, and vascular biology, 25(11), 2435-2440 (2005-09-17)
Angiotensin-converting enzyme inhibition (ACEI) increases vascular tissue plasminogen activator (t-PA) release through endogenous bradykinin (BK). We tested the hypothesis that gender influences the effect of ACEI on t-PA release. We measured the effect of intra-arterial enalaprilat (0.33 microg/min per 100
Mapping the interaction of bradykinin 1-5 with the exodomain of human protease activated receptor 4.
Marvin T Nieman et al.
FEBS letters, 579(1), 25-29 (2004-12-29)
The angiotensin converting enzyme breakdown product of bradykinin, bradykinin 1-5 (RPPGF), inhibits thrombin-induced human or mouse platelet aggregation. RPPGF binds to the exodomain of human protease-activated receptor 1 (PAR1). Studies determined if RPPGF also binds to the exodomain of human
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持